Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune ...

Apple CEO Tim Cook was in attendance at President Trump’s inauguration today in Washington, D.C., and has taken to social media to promise “continued innovation and jobs” for the United States.

Thanks for joining us at Al Jazeera Sport. Brighton beat Manchester United in Matchweek 22 of the English Premier League season. Goals from Yankuba Minteh, Karou Mitoma and Giorginio Rutter sealed ...

After Amad Diallo's midweek hattrick for Manchester United, Ruben Amorim will hope Sunday's meeting with Brighton is a little less eventful than trailing Southampton until the 82nd minute.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold. The discovery, led by researchers at Penn State, could eliminate the need for refrigeration for ...

These companies valuations have fluctuated since - Exelixis' is now valued at $10.65bn, Genmab, $13.7bn, Alnylam, $32.4bn, BioMarin, $11.7bn, and United Therapeutics, $16.1bn, while Sarepta's ...